Paving a Medtech Access Path in Europe: An Interview with Lieven Annemans

article image

Belgian health economist Lieven Annemans says Europe has fallen short in giving the most innovative new medical technologies a chance to prove themselves. But specialized innovation pathways are increasingly cropping up in different countries, and Annemans is floating a “Value of Innovation and Partnership” model that he hopes will facilitate a systematic response to the problem. He spoke to Market Pathways about his proposal.

Efforts to launch a potentially transformative medical technology often run into this paradoxical challenge: contentions that the technology can change the value proposition in healthcare need to be proven by putting it to the test in real clinical care, but healthcare systems are wary and often lack the frameworks to adopt a new, high-price-tag offering without that level of proof already in hand.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: